

# Brian E Lacy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3725802/publications.pdf>

Version: 2024-02-01

120  
papers

9,203  
citations

81889

39  
h-index

40976

93  
g-index

120  
all docs

120  
docs citations

120  
times ranked

6916  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bowel Disorders. <i>Gastroenterology</i> , 2016, 150, 1393-1407.e5.	1.3	1,912
2	Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1547-1561.	0.4	595
3	American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S2-S26.	0.4	503
4	Irritable Bowel Syndrome. <i>New England Journal of Medicine</i> , 2017, 376, 2566-2578.	27.0	439
5	ACG and CAG Clinical Guideline: Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , 2017, 112, 988-1013.	0.4	431
6	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1044-1060.	3.7	423
7	ACG Clinical Guideline: Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 17-44.	0.4	341
8	Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1350-1365.	0.4	335
9	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, 21-39.	0.4	303
10	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1290-1300.	0.4	269
11	Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. <i>Gastroenterology</i> , 2015, 149, 340-349.e2.	1.3	262
12	Mechanisms, Evaluation, and Management of Chronic Constipation. <i>Gastroenterology</i> , 2020, 158, 1232-1249.e3.	1.3	261
13	The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1367-1374.	0.4	258
14	Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids. <i>American Journal of Gastroenterology</i> , 2015, 110, 979-984.	0.4	170
15	Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. <i>Gastroenterology</i> , 2016, 150, 911-917.	1.3	154
16	Physician Burnout: The Hidden Health Care Crisis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 311-317.	4.4	140
17	The Diagnosis of Gastroesophageal Reflux Disease. <i>American Journal of Medicine</i> , 2010, 123, 583-592.	1.5	107
18	Gastroparesis. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 20-24.	2.2	92

#	ARTICLE	IF	CITATIONS
19	Lubiprostone. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 345-351.	2.2	83
20	Management Options for Patients With GERD and Persistent Symptoms on Proton Pump Inhibitors: Recommendations From an Expert Panel. <i>American Journal of Gastroenterology</i> , 2018, 113, 980-986.	0.4	78
21	Anatomy and Physiology of the Small Bowel. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2017, 27, 1-13.	1.4	74
22	Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. <i>American Journal of Gastroenterology</i> , 2017, 112, 365-374.	0.4	70
23	Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 233-243.	0.4	69
24	Functional Dyspepsia Is Associated With Sleep Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 410-414.	4.4	67
25	Chronic nausea and vomiting: evaluation and treatment. <i>American Journal of Gastroenterology</i> , 2018, 113, 647-659.	0.4	64
26	Linacotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0134349.	2.5	61
27	Opioid-Induced Esophageal Dysfunction: Differential Effects of Type and Dose. <i>American Journal of Gastroenterology</i> , 2019, 114, 1464-1469.	0.4	58
28	Safety and Tolerability of Transoral Bravo Capsule Placement After Transnasal Manometry Using a Validated Conversion Factor. <i>American Journal of Gastroenterology</i> , 2007, 102, 24-32.	0.4	57
29	Functional Dyspepsia and Gastroparesis: One Disease or Two?. <i>American Journal of Gastroenterology</i> , 2012, 107, 1615-1620.	0.4	56
30	Low-Dose Linacotide (72µg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2018, 113, 105-114.	0.4	55
31	Review: The treatment of irritable bowel syndrome. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 221-238.	3.2	52
32	Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 143-152.	1.8	52
33	Management of Chronic Abdominal Distension and Bloating. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 219-231.e1.	4.4	52
34	Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 892-902.	1.5	49
35	A Prospective Study to Compare a Symptom-Based Reflux Disease Questionnaire to 48-h Wireless pH Monitoring for the Identification of Gastroesophageal Reflux (revised 2-26-11). <i>American Journal of Gastroenterology</i> , 2011, 106, 1604-1611.	0.4	48
36	Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987895.	3.2	48

#	ARTICLE	IF	CITATIONS
37	Gastrointestinal Motility Disorders: An Update. <i>Digestive Diseases</i> , 2006, 24, 228-242.	1.9	45
38	Eluxadolone Efficacy in IBS-D Patients Who Report Prior Loperamide Use. <i>American Journal of Gastroenterology</i> , 2017, 112, 924-932.	0.4	43
39	Gastroparesis: Medical and Therapeutic Advances. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2231-2240.	2.3	42
40	Gastrointestinal Manifestations of Rheumatological Diseases. <i>American Journal of Gastroenterology</i> , 2019, 114, 1441-1454.	0.4	38
41	Esophageal Motility Disorders. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 652-658.	2.2	37
42	Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S230-S242.	2.2	36
43	The Science, Evidence, and Practice of Dietary Interventions in Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1899-1906.	4.4	33
44	Gastric Motility, Gastroparesis, and Gastric Stimulation. <i>Surgical Clinics of North America</i> , 2005, 85, 967-987.	1.5	31
45	Chronic constipation: new diagnostic and treatment approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 233-247.	3.2	31
46	Postobesity Surgery Esophageal Dysfunction: A Combined Cross-Sectional Prevalence Study and Retrospective Analysis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1669-1680.	0.4	31
47	IBS Patients' Willingness to Take Risks With Medications. <i>American Journal of Gastroenterology</i> , 2012, 107, 804-809.	0.4	30
48	Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations. <i>Journal of the American Association of Nurse Practitioners</i> , 2016, 28, 393-404.	0.9	30
49	AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 491-500.	4.4	28
50	Identification of Quality Measures for Performance of and Interpretation of Data From Esophageal Manometry. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 526-534.e1.	4.4	27
51	Variation in Care for Patients with Irritable Bowel Syndrome in the United States. <i>PLoS ONE</i> , 2016, 11, e0154258.	2.5	26
52	A Novel, Duodenal-Release Formulation of a Combination of Caraway Oil and L-Menthol for the Treatment of Functional Dyspepsia: A Randomized Controlled Trial. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00021.	2.5	25
53	Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 817-830.	3.7	23
54	Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877167.	3.2	22

#	ARTICLE	IF	CITATIONS
55	A 32-Year-Old Woman With Chronic Abdominal Pain. JAMA - Journal of the American Medical Association, 2008, 299, 555.	7.4	21
56	Functional Dyspepsia: Clinical Symptoms, Psychological Findings, and GCSI Scores. Digestive Diseases and Sciences, 2019, 64, 1281-1287.	2.3	21
57	Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD). American Journal of Gastroenterology, 2018, 113, 39-48.	0.4	20
58	Diagnosing Small Intestinal Bacterial Overgrowth: A Comparison of Lactulose Breath Tests to Small Bowel Aspirates. Digestive Diseases and Sciences, 2021, 66, 2042-2050.	2.3	19
59	The Effects of Nebulized Albuterol on Esophageal Function in Asthmatic Patients. Digestive Diseases and Sciences, 2008, 53, 2627-2633.	2.3	18
60	Common anorectal disorders: Diagnosis and treatment. Current Gastroenterology Reports, 2009, 11, 413-419.	2.5	18
61	A System to Assess the Competency for Interpretation of Esophageal Manometry Identifies Variation in Learning Curves. Clinical Gastroenterology and Hepatology, 2017, 15, 1708-1714.e3.	4.4	18
62	Gastric Emptying Scans: Poor Adherence to National Guidelines. Digestive Diseases and Sciences, 2021, 66, 2897-2906.	2.3	18
63	Patients With Irritable Bowel Syndrome Are Willing to Take Substantial Medication Risks for Symptom Relief. Clinical Gastroenterology and Hepatology, 2021, 19, 80-86.	4.4	18
64	The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum. Clinical and Translational Gastroenterology, 2015, 6, e106.	2.5	17
65	Diagnostic Evaluation of Gastric Motor and Sensory Disorders. American Journal of Gastroenterology, 2021, 116, 2345-2356.	0.4	17
66	The Clinical Utility of Esophageal Manometry. Journal of Clinical Gastroenterology, 2009, 43, 809-815.	2.2	16
67	Dietary Interventions and Irritable Bowel Syndrome: A Review of the Evidence. Current Gastroenterology Reports, 2016, 18, 41.	2.5	16
68	Rifaximin and eluxadoline "newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?. Expert Opinion on Pharmacotherapy, 2016, 17, 311-322.	1.8	16
69	Functional Dyspepsia: Time to Change Clinical Trial Design?. American Journal of Gastroenterology, 2010, 105, 2525-2529.	0.4	15
70	Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. American Journal of Gastroenterology, 2021, 116, 1601-1611.	0.4	15
71	Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options. American Journal of Gastroenterology, 2021, 116, 1587-1600.	0.4	15
72	Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 2021, 54, 98-108.	3.7	15

#	ARTICLE	IF	CITATIONS
73	Medication Risk-Taking Behavior in Functional Dyspepsia Patients. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e69.	2.5	14
74	Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards?. <i>American Journal of Gastroenterology</i> , 2018, 113, 167-169.	0.4	14
75	On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 926-935.	1.5	13
76	Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481881832.	3.2	13
77	Tolerability and Clinical Utility of the Bravo pH Capsule in Children. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 514-519.	2.2	12
78	Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984129.	3.2	12
79	The willingness of patients with gastroparesis to take risks with medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 429-436.	3.7	12
80	Polymorphisms of 5-HTT LPR and GN <sup>23</sup> 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. <i>American Journal of Gastroenterology</i> , 2017, 112, 903-909.	0.4	11
81	Symptomatic Management of Gastroparesis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 55-70.	1.4	11
82	Prucalopride for chronic constipation. <i>Drugs of Today</i> , 2009, 45, 843.	1.1	10
83	Clinical Utility of the Wireless pH Capsule. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 429-435.	2.2	9
84	Negative Is Positive. <i>American Journal of Gastroenterology</i> , 2016, 111, 1505.	0.4	8
85	Update on the Management of Chronic Constipation. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 126-134.	0.8	8
86	Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medications. <i>PLoS ONE</i> , 2021, 16, e0243318.	2.5	7
87	Management of irritable bowel syndrome with diarrhea: focus on eluxadoline. <i>Current Medical Research and Opinion</i> , 2021, 37, 567-578.	1.9	6
88	Neuroenteric Stimulation for Gastroparesis. <i>Current Treatment Options in Gastroenterology</i> , 2015, 13, 409-417.	0.8	5
89	Introduction to the 80% by 2018 Special Issue. <i>American Journal of Gastroenterology</i> , 2018, 113, 1737-1738.	0.4	5
90	Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e682-e695.	4.4	5

#	ARTICLE	IF	CITATIONS
91	Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder. <i>American Journal of Gastroenterology</i> , 2017, 112, 1619-1620.	0.4	4
92	Another Reason to Avoid the Gluten-Free Fad?. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 184-185.	4.4	4
93	Eating Disorders: Diagnosis and Management Considerations for the IBD Practice. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 936-946.	1.9	4
94	A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia. <i>BMC Gastroenterology</i> , 2022, 22, 105.	2.0	4
95	Recent Advances in the Management of Difficult Constipation. <i>Current Gastroenterology Reports</i> , 2012, 14, 306-312.	2.5	3
96	Does Yoga Help Patients With Irritable Bowel Syndrome?. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1732-1734.	4.4	3
97	Lymphocytic Esophagitis: Assessing Risk Factors and Clinical Outcomes. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3976-3984.	2.3	3
98	Partnering with gastroenterologists to evaluate patients with chronic constipation. <i>MedGenMed: Medscape General Medicine</i> , 2005, 7, 19.	0.2	3
99	Linaclotide utilization and potential for off-label use and misuse in three European countries. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211009.	3.2	3
100	The American Journal of Gastroenterology in 2016: Where Have We Been? Where Are We Going?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1-3.	0.4	2
101	Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110017.	3.2	2
102	Extent of eosinophilic esophagitis predicts response to treatment. <i>Endoscopy International Open</i> , 2021, 09, E1234-E1242.	1.8	2
103	Pyloric dilation with EsoFLIP: Time to "eflip" treatment options for refractory gastroparesis?. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 495-497.	1.0	2
104	A Pragmatic Approach to the Evaluation and Treatment of Abdominal Bloating. <i>American Journal of Gastroenterology</i> , 2022, 117, 701-705.	0.4	2
105	Clinical Pearls for Irritable Bowel Syndrome. <i>Gastroenterology Nursing</i> , 2014, 37, 392-405.	0.4	1
106	Response to Croteau and Barkin. <i>American Journal of Gastroenterology</i> , 2017, 112, 1617.	0.4	1
107	Response to Marlicz et al. <i>American Journal of Gastroenterology</i> , 2018, 113, 781.	0.4	1
108	Putting Patients First. <i>American Journal of Gastroenterology</i> , 2018, 113, 1.	0.4	1

#	ARTICLE	IF	CITATIONS
109	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1254-1255.	3.7	1
110	Controversies in Gastroparesis: Discussing the Sticky Points. <i>American Journal of Gastroenterology</i> , 2021, 116, 1572-1576.	0.4	1
111	The "Changing Landscapes" Special Edition. <i>American Journal of Gastroenterology</i> , 2021, 116, 1969-1969.	0.4	1
112	Hot Topics in Primary Care: Role of the Microbiome in Disease: Implications for Treatment of Irritable Bowel Syndrome. <i>Journal of Family Practice</i> , 2017, 66, S40-S45.	0.2	1
113	How effective is tegaserod for the treatment of female patients with mixed subtype IBS?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2008, 5, 664-665.	1.7	0
114	No Results? No Problem! Why We Are Publishing Methods of a Landmark Study With Results Still Pending. <i>American Journal of Gastroenterology</i> , 2017, 112, 1747-1748.	0.4	0
115	Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating "a step in the right direction for targeted treatment? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 198-199.	3.7	0
116	Gastric POEM for gastroparesis: Panacea, placebo, or pathway to the future?. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 45-47.	1.0	0
117	70-Year-Old Man With Chronic Nausea and Vomiting. <i>Mayo Clinic Proceedings</i> , 2021, 96, 3142-3146.	3.0	0
118	How Your Writing Can Succeed: Getting a Manuscript Accepted by The American Journal of Gastroenterology. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, .	0.4	0
119	Reflections on Our Editorship of The American Journal of Gastroenterology. <i>American Journal of Gastroenterology</i> , 2021, 116, 2313-2315.	0.4	0
120	A Practical Approach to the Diagnosis and Treatment of Abdominal Bloating and Distension.. <i>Gastroenterology and Hepatology</i> , 2022, 18, 75-84.	0.1	0